Lack of national pharmacare program makes it hard to negotiate better drug prices. The B.C. government says it won't cover the cost of a breakthrough treatment for hepatitis C for Nikky Davies, who contracted the virus through tainted blood she was administered in hospital.
A Nanaimo, B.C., woman who contracted the hepatitis C virus through tainted blood has been denied a blockbuster new medication the province says is extremely expensive and would bankru
The Health Care Authority on Monday reached a settlement agreement in a class action lawsuit that sought broader coverage of costly hepatitis C drugs for Medicaid patients in Washington state.
The settlement has yet to be approved by a judge but lawyers are hopeful it will be soon.
In the past several years, multiple pharmaceutical companies nationwide have developed direct-acting antiviral drugs that cure hepatitis C in more than 90 percent of patient
Friday, October-28-16
News in Brief
Restricted Reimbursement for DAAs Hinders Progress Towards Global Hepatitis C Eradication Goal
October 27, 2016
There are significant differences in the criteria for reimbursing for direct-acting antivirals (DAAs) for patients with hepatitis C virus (HCV) among the provinces in Canada, according to the results of a recent study. Conducted by Alison Marshall, MA, of The Kirby Institute, and colleagues, the study...
